loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Quemliclustat, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Quemliclustat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: Ab-680, 2105904-82-1, Ab680, Quemliclustat [usan], J6k8wsv73a, Chembl4471306
    Molecular Formula
    C20H24ClFN4O9P2
    Molecular Weight
    580.8  g/mol
    InChI Key
    MFYLCAMJNGIULC-KCVUFLITSA-N
    FDA UNII
    J6K8WSV73A
    Quemliclustat is a small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon administration, quemliclustat targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
    2.1.2 InChI
    InChI=1S/C20H24ClFN4O9P2/c1-10(11-4-2-3-5-13(11)22)24-14-6-16(21)25-19-12(14)7-23-26(19)20-18(28)17(27)15(35-20)8-34-37(32,33)9-36(29,30)31/h2-7,10,15,17-18,20,27-28H,8-9H2,1H3,(H,24,25)(H,32,33)(H2,29,30,31)/t10-,15+,17+,18+,20+/m0/s1
    2.1.3 InChI Key
    MFYLCAMJNGIULC-KCVUFLITSA-N
    2.1.4 Canonical SMILES
    CC(C1=CC=CC=C1F)NC2=CC(=NC3=C2C=NN3C4C(C(C(O4)COP(=O)(CP(=O)(O)O)O)O)O)Cl
    2.1.5 Isomeric SMILES
    C[C@@H](C1=CC=CC=C1F)NC2=CC(=NC3=C2C=NN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(CP(=O)(O)O)O)O)O)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    J6K8WSV73A
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Ab680

    2.3.2 Depositor-Supplied Synonyms

    1. Ab-680

    2. 2105904-82-1

    3. Ab680

    4. Quemliclustat [usan]

    5. J6k8wsv73a

    6. Chembl4471306

    7. [[(2~{r},3~{s},4~{r},5~{r})-5-[6-chloranyl-4-[[(1~{s})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic Acid

    8. [[(2r,3s,4r,5r)-5-[6-chloro-4-[[(1s)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic Acid

    9. Unii-j6k8wsv73a

    10. Quemliclustat [inn]

    11. Cd73 Inhibitor Ab-680

    12. Schembl19100484

    13. Gtpl10707

    14. Ex-a4998

    15. Bdbm50527134

    16. Who 11621

    17. Ac-36768

    18. Ba178946

    19. Hy-125286

    20. Cs-0090231

    21. F78354

    22. (((((2r,3s,4r,5r)-5-(6-chloro-4-(((s)-1-(2-fluorophenyl)ethyl)amino)-1h-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic Acid

    23. (((2r,3s,4r,5r)-5-(6-chloro-4-((s)-1-(2-fluorophenyl)ethylamino)-1h-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-ylmethoxy)(hydroxy)phosphorylmethyl)phosphonic Acid

    24. 1h-pyrazolo[3,4-b]pyridin-4-amine, 6-chloro-n-[(1s)-1-(2-fluorophenyl)ethyl]-1-[5-o-[hydroxy(phosphonomethyl)phosphinyl]-beta-d-ribofuranosyl]-

    25. 2-chloro-n6 -[(1s)-1-(2-fluorophenyl)ethyl]-8-aza-1,7- Dicarbaadenosine 5'- (trihydrogen 2-carbadiphosphate)

    26. Qdh

    2.4 Create Date
    2017-10-07
    3 Chemical and Physical Properties
    Molecular Weight 580.8 g/mol
    Molecular Formula C20H24ClFN4O9P2
    XLogP3-0.7
    Hydrogen Bond Donor Count6
    Hydrogen Bond Acceptor Count13
    Rotatable Bond Count9
    Exact Mass580.0691082 g/mol
    Monoisotopic Mass580.0691082 g/mol
    Topological Polar Surface Area197 Ų
    Heavy Atom Count37
    Formal Charge0
    Complexity893
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Immune Checkpoint Inhibitors

    Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. (See all compounds classified as Immune Checkpoint Inhibitors.)

    Post Enquiry
    POST ENQUIRY